Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD9056 in Moderate to Severe COPD
2005-004110-32Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Sep 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in chronic obstructive pulmonary disease (COPD) comparing AZD9056 400 mg with Placebo (2 arms). Primary endpoints: Exercise tolerance (6-minute walk test), COPD symptoms (Bronkotest diary card) and 5 more. Started Sep 2005; status: completed.
02
Drugs
AZD9056
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on 2005-004110-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-004110-32.